Cargando…
Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2
The outbreak of the coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 triggered a global pandemic where control is needed through therapeutic and preventive interventions. This study aims to identify natural compounds that could affect the fusion between the vira...
Autores principales: | Ohishi, Tomokazu, Hishiki, Takayuki, Baig, Mirza S., Rajpoot, Sajjan, Saqib, Uzma, Takasaki, Tomohiko, Hara, Yukihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278780/ https://www.ncbi.nlm.nih.gov/pubmed/35830431 http://dx.doi.org/10.1371/journal.pone.0271112 |
Ejemplares similares
-
Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses
por: Joseph, Jeswin, et al.
Publicado: (2021) -
Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells
por: Baig, Mirza S., et al.
Publicado: (2020) -
The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection
por: Henss, Lisa, et al.
Publicado: (2021) -
A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor
por: Rajpoot, Sajjan, et al.
Publicado: (2021) -
Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases
por: Dinda, Biswanath, et al.
Publicado: (2023)